[
  {
    "ts": null,
    "headline": "Is Eli Lilly a Buy Before 2026?",
    "summary": "Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.",
    "url": "https://finnhub.io/api/news?id=3da2c3e464d2569ba59a655eef509d331df2fc6f6cea6901d15449fd3a816c88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765903800,
      "headline": "Is Eli Lilly a Buy Before 2026?",
      "id": 137806013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.",
      "url": "https://finnhub.io/api/news?id=3da2c3e464d2569ba59a655eef509d331df2fc6f6cea6901d15449fd3a816c88"
    }
  },
  {
    "ts": null,
    "headline": "Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?",
    "summary": "In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...",
    "url": "https://finnhub.io/api/news?id=aa652cf02452608c61d6e1b27efd4eaec79cab9de175e374eb8a29efa06575e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765901243,
      "headline": "Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?",
      "id": 137806014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...",
      "url": "https://finnhub.io/api/news?id=aa652cf02452608c61d6e1b27efd4eaec79cab9de175e374eb8a29efa06575e2"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in J.P. Morgan Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=129044a97e5d6fb4f4b6b566bb67208edbe17829ac8020e27a276473b2e803aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765897200,
      "headline": "Lilly to participate in J.P. Morgan Healthcare Conference",
      "id": 137806015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=129044a97e5d6fb4f4b6b566bb67208edbe17829ac8020e27a276473b2e803aa"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
    "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
    "url": "https://finnhub.io/api/news?id=b205aaf745a91832efb7028216fa23ee36e162fc0c95e8c93dfadc6471c813a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765896240,
      "headline": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
      "id": 137806016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
      "url": "https://finnhub.io/api/news?id=b205aaf745a91832efb7028216fa23ee36e162fc0c95e8c93dfadc6471c813a4"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly",
    "summary": "2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.",
    "url": "https://finnhub.io/api/news?id=e21ead2a29461da5f5c9df69ce57965b4b8b9656a1ada41d3c471f7ec80f00fa",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765895349,
      "headline": "Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly",
      "id": 137812256,
      "image": "https://image.cnbcfm.com/api/v1/image/107393750-1711561383116-gettyimages-88296329-ti0300206.jpeg?v=1759260598&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S. ",
      "url": "https://finnhub.io/api/news?id=e21ead2a29461da5f5c9df69ce57965b4b8b9656a1ada41d3c471f7ec80f00fa"
    }
  },
  {
    "ts": null,
    "headline": "5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026",
    "summary": "MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors",
    "url": "https://finnhub.io/api/news?id=9bb80245a64b446ebbcb262a5774e0997879e67f6d707699a528d4054434814d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894980,
      "headline": "5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026",
      "id": 137804189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors",
      "url": "https://finnhub.io/api/news?id=9bb80245a64b446ebbcb262a5774e0997879e67f6d707699a528d4054434814d"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
    "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
    "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894620,
      "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
      "id": 137816785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
      "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
    "url": "https://finnhub.io/api/news?id=99d3335d59ca228c90eebb78faca412751d09dc46758a0c7613ed10158ac7b5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894190,
      "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
      "id": 137804242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More",
      "url": "https://finnhub.io/api/news?id=99d3335d59ca228c90eebb78faca412751d09dc46758a0c7613ed10158ac7b5b"
    }
  },
  {
    "ts": null,
    "headline": "Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing",
    "summary": "BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.",
    "url": "https://finnhub.io/api/news?id=fdb07db1a9646bd1dd7441e82659aad5cccc8c618f12b613482e08c261c09753",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765891800,
      "headline": "Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing",
      "id": 137806019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.",
      "url": "https://finnhub.io/api/news?id=fdb07db1a9646bd1dd7441e82659aad5cccc8c618f12b613482e08c261c09753"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
    "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
    "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765886580,
      "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
      "id": 137816786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
      "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Eli Lilly Be in 10 Years?",
    "summary": "In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.",
    "url": "https://finnhub.io/api/news?id=a2b366687fc897cf7d0c2d74219745dcfb6c8c00604e5c104c94abe7d5b03502",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765881300,
      "headline": "Where Will Eli Lilly Be in 10 Years?",
      "id": 137806020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.",
      "url": "https://finnhub.io/api/news?id=a2b366687fc897cf7d0c2d74219745dcfb6c8c00604e5c104c94abe7d5b03502"
    }
  },
  {
    "ts": null,
    "headline": "China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?",
    "summary": "Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as \"historic\" and \"the beginning of the end\" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi",
    "url": "https://finnhub.io/api/news?id=a8126a12dcdce74600e4e71d8cd4986e0c53ca48efa799b482829dcf5fafb6ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765877400,
      "headline": "China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?",
      "id": 137816787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as \"historic\" and \"the beginning of the end\" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi",
      "url": "https://finnhub.io/api/news?id=a8126a12dcdce74600e4e71d8cd4986e0c53ca48efa799b482829dcf5fafb6ff"
    }
  },
  {
    "ts": null,
    "headline": "Europe's best-performing stock is up 1,400% this year. Here's what's next",
    "summary": "Abivax stock has far outperformed the broader index with a stellar performance, even as the company is making big financial losses.",
    "url": "https://finnhub.io/api/news?id=0acd74fc7e9d815ee553a4c7c54c258d127aed13040b960ccbf88def799c1cc3",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765868014,
      "headline": "Europe's best-performing stock is up 1,400% this year. Here's what's next",
      "id": 137803098,
      "image": "https://image.cnbcfm.com/api/v1/image/108242262-1765880709574-gettyimages-2199985242-FRANCE_GROWTH.jpeg?v=1765880736&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Abivax stock has far outperformed the broader index with a stellar performance, even as the company is making big financial losses. ",
      "url": "https://finnhub.io/api/news?id=0acd74fc7e9d815ee553a4c7c54c258d127aed13040b960ccbf88def799c1cc3"
    }
  },
  {
    "ts": null,
    "headline": "Scotiabank Remains Bullish on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]",
    "url": "https://finnhub.io/api/news?id=e44b4d084e851105213011410d09422ff0b57b7b131de6b685c89d6ce31ba4b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765856767,
      "headline": "Scotiabank Remains Bullish on Eli Lilly and Company (LLY)",
      "id": 137798560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]",
      "url": "https://finnhub.io/api/news?id=e44b4d084e851105213011410d09422ff0b57b7b131de6b685c89d6ce31ba4b6"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks: Outlook For 2026",
    "summary": "I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare outlook and LLY and NVO stocks in particular.",
    "url": "https://finnhub.io/api/news?id=bb963d6ac24b258f78b70dab9f81fec1aac1edfcc26ca507edaadfc7e8b50744",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765852120,
      "headline": "Healthcare Stocks: Outlook For 2026",
      "id": 137799757,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1557045133/image_1557045133.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare outlook and LLY and NVO stocks in particular.",
      "url": "https://finnhub.io/api/news?id=bb963d6ac24b258f78b70dab9f81fec1aac1edfcc26ca507edaadfc7e8b50744"
    }
  }
]